https://www.selleckchem.com/pr....oducts/acetalax-oxyp
6, p=0.47). There was a significant positive correlation between CMTESv2 and the age of patients in Groups I (p=0.027) and II (p=0.023), indicating that clinical severity progressed with age in these patients. To optimize the selection of CMT patients carrying MPZ mutations for the upcoming trials, inclusion criteria should take into account the pathophysiology of the disease (upregulated UPR). Recruited patients should have a mild to moderate disease severity and a disease onset at between 18 and 50years, as thes
Like
Comment
Share
